目的 探讨止喘灵口服液联合特布他林治疗儿童支气管哮喘的临床疗效。方法 选取2021年10月—2022年10月黄河三门峡医院收治的110例支气管哮喘患儿，以随机数字表分为对照组和治疗组，每组55例。对照组雾化吸入硫酸特布他林雾化吸入用溶液治疗，体质量≥20 kg的患儿以5 mg药液雾化吸入，3次/d；体质量＜20 kg的患儿以2.5 mg药液雾化吸入，4次/d。治疗组在对照组治疗基础上增加止喘灵口服液治疗，硫酸特布他林雾化吸入用溶液用药方案与对照组相同，止喘灵口服液10 mL/次，3次/d。两组均以7 d为1疗程，治疗1个疗程。观察两组临床疗效，比较治疗前后两组肺功能指标、相关量表评分、气道炎症指标和血清炎症因子水平。结果 治疗后，治疗组总有效率是92.73%，显著高于对照组的80.00%（P＜0.05）。治疗后，两组最大呼气第1秒容积（FEV1）、用力肺活量（FVC）、最大呼气峰流速（PEF）、最大呼气第1秒容积/用力肺活量（FEV1/FVC）均显著提高（P＜0.05）；治疗后，治疗组FEV1、FVC、PEF、FV1/FVC高于对照组（P＜0.05）。治疗后，两组儿童哮喘控制测试评分（C-ACT）、儿科哮喘生活质量调查问卷（PAQLQ）评分均升高（P＜0.05）；治疗后治疗组C-ACT、PAQLQ高于对照组（P＜0.05）。治疗后，两组痰中嗜酸性粒细胞（EOS）比例、呼出气一氧化氮（FeNO）水平均显著降低（P＜0.05）；治疗后，治疗组患者痰中EOS比例、呼出气FeNO水平低于对照组（P＜0.05）。治疗后，两组白细胞介素-8（IL-8）、白细胞介素-17（IL-17）、C反应蛋白（CRP）水平均显著降低（P＜0.05）；治疗后，治疗组IL-8、IL-17、CRP水平均低于对照组（P＜0.05）。结论 止喘灵口服液联合特布他林治疗儿童支气管哮喘效果良好，能提升肺功能指标，降低患儿的气道炎症指标和血清炎症因子水平，改善患儿生活质量。

Objective To study the clinical efficacy of Zhichuanling Oral Liquid combined with terbutaline in treatment of bronchial asthma in children. Methods A total of 110 children with bronchial asthma admitted to Yellow River Sanmenxia Hospital from October 2021 to October 2022 were selected and divided into control group and treatment group by random number table, with 55 cases in each group. Children in control group were nebulized inhalation of Terbutaline Sulfate Nebuliser Solution, for children with body weight of ≥ 20 kg, 5 mg of the drug solution is nebulized and inhaled three times daily. For children with body weight of < 20 kg, 2.5 mg of the drug solution should be nebulized and inhaled 4 times daily. Children in treatment group were treated with Zhichuanling Oral Liquid on the basis of control group’s treatment. The medication regimen for terbutaline sulfate nebulized inhalation solution was the same as that of control group. The dosage of Zhichuanling Oral Liquid was 10 mL each time, three times daily. Both groups were treated for 7 d as one course of treatment, with one course of treatment. The clinical efficacy of two groups was observed, and the pulmonary function indicators, related scale scores, airway inflammation indicators and serum inflammatory factor levels of two groups before and after treatment were compared. Results After treatment, the total effective rate of treatment group was 92.73%, significantly higher than that of control group (80.00%, P < 0.05). After treatment, FEV1, FVC, PEF, and FEV1/FVC in both groups were significantly increased (P < 0.05). After treatment, the levels of FEV1, FVC, PEF, and FV1/FVC in treatment group were higher than those in control group (P < 0.05). After treatment, the scores of C-ACT and PAQLQ in both groups increased (P < 0.05). After treatment, the C-ACT and PAQLQ in treatment group were higher than those in control group (P < 0.05). After treatment, the proportion of EOS in sputum and the level of FeNO in both groups were significantly decreased (P < 0.05). After treatment, the proportion of EOS in sputum and the FeNO level in exhaled breath of patients in treatment group were lower than those in control group (P < 0.05). After treatment, the levels of IL-8, IL-17, and CRP in both groups were significantly decreased (P < 0.05). After treatment, the levels of IL-8, IL-17, and CRP in treatment group were all lower than those in control group (P < 0.05). Conclusion Zhichuanling Oral Liquid combined with terbutaline is clinically significant in treatment of bronchial asthma in children, can improve the lung function of children, reduce airway inflammation indicators and serum inflammatory factor levels, which can improve life quality of children.

R974;R985

河南省医学科技攻关联合共建项目（20221041）